

Journal Pre-proof



JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B: REEF-2

Kosh Agarwal, Maria Buti, Florian van Bömmel, Pietro Lampertico, Ewa Janczewska, Marc Bourliere, Thomas Vanwolleghem, Oliver Lenz, Thierry Verbinnen, Thomas N. Kakuda, Cristiana Mayer, John Jezorwski, Daniel Muenz, Maria Beumont, Ronald Kalmeijer, Michael Biermer, Isabelle Lonjon-Domanec

PII: S0168-8278(24)00231-9

DOI: <https://doi.org/10.1016/j.jhep.2024.03.046>

Reference: JHEPAT 9578

To appear in: *Journal of Hepatology*

Received Date: 23 August 2023

Revised Date: 6 February 2024

Accepted Date: 21 March 2024

Please cite this article as: Agarwal K, Buti M, van Bömmel F, Lampertico P, Janczewska E, Bourliere M, Vanwolleghem T, Lenz O, Verbinnen T, Kakuda TN, Mayer C, Jezorwski J, Muenz D, Beumont M, Kalmeijer R, Biermer M, Lonjon-Domanec I, JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B: REEF-2, *Journal of Hepatology* (2024), doi: <https://doi.org/10.1016/j.jhep.2024.03.046>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.



CHB diagnosis
NA suppressed
HBeAg–

Active treatment group:

JNJ-3989 (200 mg SC Q4W) +
JNJ-6379 (250 mg PO QD) + NA
N = 85

Control group:

JNJ-3989 placebo +
JNJ-6379 placebo + NA
N = 45

Results

<ul style="list-style-type: none"> • Mean HBsAg decline = $-1.89 \log_{10}$ IU/mL • 15.6% had HBV DNA <LLOQ and HBsAg <100 IU/mL (partial cure) 	<p>Week 48 (end of all treatment)</p>	<ul style="list-style-type: none"> • Mean HBsAg decline = $-0.06 \log_{10}$ IU/mL • 0 had HBV DNA <LLOQ and HBsAg <100 IU/mL (partial cure)
<p>No functional cure (primary endpoint)</p>	<p>Follow-up Week 24</p>	<p>No functional cure (primary endpoint)</p>
<ul style="list-style-type: none"> • No functional cure • 81.5% had HBsAg reductions from baseline $>1 \log_{10}$ IU/mL • 46.9% had HBsAg <100 IU/mL • Lower frequency of HBV DNA relapse and ALT increases • 9.1% restarted NA 	<p>Follow-up Week 48 (end of study)</p>	<ul style="list-style-type: none"> • No functional cure • 12.5% had HBsAg reductions from baseline $>1 \log_{10}$ IU/mL • 15.0% had HBsAg <100 IU/mL • Higher frequency of HBV DNA relapse and ALT increases • 26.8% restarted NA

JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B: REEF-2

Kosh Agarwal,¹ Maria Buti,² Florian van Bömmel,³ Pietro Lampertico,^{4,5} Ewa Janczewska,⁶ Marc Bourliere,⁷ Thomas Vanwolleghem,^{8,9} Oliver Lenz,¹⁰ Thierry Verbinnen,¹⁰ Thomas N. Kakuda,¹¹ Cristiana Mayer,¹² John Jezorwski,¹² Daniel Muenz,¹³ Maria Beumont,¹⁰ Ronald Kalmeijer,¹² Michael Biermer,¹⁰ Isabelle Lonjon-Domanec¹⁰

¹Institute of Liver Studies, King's College Hospital, London, England; ²Hospital General Universitari Valle Hebron and CIBER-EHD del Instituto Carlos III, Barcelona, Spain; ³Leipzig University Medical Center, Department of Medicine II, Division of Hepatology, Leipzig, Germany; ⁴Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy; ⁵CRC "A.M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ⁶Faculty of Health Sciences, Medical University of Silesia, Katowice, Poland; ⁷Hôpital Saint Joseph, Marseille, France; ⁸Antwerp University Hospital, Edegem, Belgium; ⁹Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium; ¹⁰Janssen Pharmaceutica NV, Beerse, Belgium; ¹¹Janssen Research & Development, LLC, Brisbane, CA, USA; ¹²Janssen Research & Development, LLC, Titusville, NJ, USA; ¹³IQVIA, Research Triangle Park, NC, USA.

Corresponding author: Kosh Agarwal, Institute of Liver Studies, King's College Hospital, Denmark Hill, London SE5 9RS, Phone: +44 7710 057631, Email: kosh.agarwal@nhs.net

Keywords: bersacapavir, CAM, capsid assembly modulator, chronic hepatitis B, finite therapy, HBV, hepatitis B virus, JNJ-56136379, JNJ-73763989, NA cessation, siRNA

Word count: 5932

Number of figures and tables: 8

Conflicts of interest: KA received grants from Abbott and MSD; served as a consultant for Janssen, Assembly, Arbutus, Immunocore, Roche, BMS, Boehringer Ingelheim, Novartis, Shinoigi, and Sobi; served as a speaker for Gilead and Sobi; and served on a data safety monitoring or advisory board for Drug Farm, NUC-B, and Aligos. MBu received grants from Gilead and speaker fees from Gilead and AbbVie. FvB received grants/research support from BMS, Gilead, Humedics, Roche, and Janssen; received honoraria or consulting fees from AbbVie, Bayer, Gilead, Eisai, Ipsen, Janssen, MSD/Merck, Novartis, and Roche; and participated in a company-sponsored speakers bureau from AbbVie, Bayer, Gilead, Eisai, Ipsen, Janssen, MedUpdate, MSD/Merck, and Novartis. PL served on advisory boards or speaker bureaus for BMS, Roche, Gilead, GSK, AbbVie, MSD, Arrowhead, Alnylam, Janssen, Spring Bank, MYR, Eiger Biopharmaceuticals, Aligos Therapeutics, and Antios Therapeutics. EJ served as a consultant for AbbVie, Gilead, and Roche; and received speaker fees from AbbVie, MSD, and Roche. MBo served as a consultant for Janssen, Gilead, MBS Pharma, MSD, GSK, and AbbVie. TVa received grants from Gilead and BMS; served as a consultant for Janssen, Gilead, and AbbVie; and received speaker fees from Gilead. DM reports relationships with Janssen Pharmaceuticals and IQVIA. OL, TVe, TNK, CM, JJ, MBe, RK, MBi, and ILD are or were Janssen employees at the time of study conduct and may hold stock in Johnson & Johnson.

Financial support: This study was sponsored by Janssen Research & Development with medical writing support provided by Kim Caldwell, PhD, of Lumanity Communications Inc., and funded by Janssen.

Author contributions: All authors were involved in the critical revisions of the manuscript and the review of important content, were accountable for all aspects of the work (accuracy and integrity), and approved the final manuscript submitted. At least 1 author had access to all of the data and can vouch for the integrity of the data analyses. OL, TVe, TNK, CM, JJ, MBe, RK, MBi, and ILD designed the protocol and analyzed the data.

ClinicalTrials.gov Identifier: NCT04129554

Abstract

Background & Aims: Functional cure (FC) for chronic hepatitis B (CHB) requires finite treatment. Two agents under investigation aimed at achieving FC are small interfering RNA JNJ-73763989 (JNJ-3989) and capsid assembly modulator JNJ-56136379 (JNJ-6379; bersacapavir).

Methods: REEF-2, a phase 2b, double-blind, placebo-controlled, randomized study (ClinicalTrials.gov Identifier: NCT04129554), enrolled 130 nucleos(t)ide analog (NA)-suppressed hepatitis B e-antigen (HBeAg)-negative CHB patients who received JNJ-3989 (200 mg subcutaneously every 4 weeks)+JNJ-6379 (250 mg oral daily)+NA (oral daily; active arm) or placebos for JNJ-3989 and JNJ-6379 + active NA (control arm) for 48 weeks followed by 48 weeks off-treatment follow-up.

Results: At Follow-up Week 24, no patients achieved the primary endpoint of FC (off-treatment hepatitis B surface antigen [HBsAg] seroclearance). No patients achieved FC at Follow-up Week 48. There was pronounced on-treatment reduction in mean HBsAg from baseline at Week 48 in the active arm versus no decline in the control arm (1.89 vs 0.06 log₁₀ IU/mL; $P = 0.001$). At Follow-up Week 48, reductions from baseline were >1 log₁₀ IU/mL in 81.5% versus 12.5% of patients in the active and control arms, respectively, and 38/81 (46.9%) patients in the active arm achieved HBsAg <100 IU/mL versus 6/40 (15.0%) patients in the control arm. Off-treatment HBV DNA relapse and alanine aminotransferase (ALT) increases were less frequent in the active arm with 7/77 (9.1%) and 11/41 (26.8%) patients in the active and control arms, respectively, restarting NA during follow-up.

Conclusions: Finite 48-week treatment with JNJ-3989+JNJ-6379+NA resulted in fewer and less severe posttreatment HBV DNA increases and ALT flares, and a higher proportion of patients

with off-treatment HBV DNA suppression, with or without HBsAg suppression, but did not result in FC.

Impact and implications

Achieving a functional cure from chronic hepatitis B (CHB) with finite treatments is a high unmet medical need. Studies in non-cirrhotic, HBsAg negative CHB patients showed higher rates of functional cure with controlled cessation of long-term nucleos(t)ide analog (NA) treatment compared with continued NA treatment, especially in patients with low levels of hepatitis B surface antigen (HBsAg; <100 IU/mL) at the time of NA withdrawal. The current study assessed the rate of functional cure and clinical outcome after controlled NA withdrawal in patients with low levels of HBsAg induced by 48-weeks of treatment with the small interfering RNA JNJ-73763989 (JNJ-3989) and the capsid assembly modulator JNJ-56136379 (JNJ-6379) plus NA versus patients who received NA treatment. Though functional cure was not achieved by any patient in either arm, the 48-week treatment regimen of JNJ-3989, JNJ-6379, and NA did result in more patients achieving pronounced reductions in HBsAg compared with the control group, with clinically meaningful reductions maintained up to 48 weeks off all treatments, as well as fewer off-treatment hepatitis B virus DNA increases and alanine transaminase flares. These findings provide valuable insights for future studies investigating potential finite treatment options and the demonstrated efficacy and safety outcomes of the study's treatment regimen may be of interest to health care providers making treatment decisions for patients with NA-suppressed HBeAg-negative CHB.

Introduction

Chronic hepatitis B virus (HBV) infection affects ~3.5% of the global population.¹ The current treatment options, pegylated interferon and nucleos(t)ide analogs (NAs), suppress viral replication,² but rarely lead to functional cure, defined as sustained off-treatment hepatitis B surface antigen (HBsAg) seroclearance.³ Thus, the search continues for a finite treatment for chronic hepatitis B (CHB) that can result in functional cure.

Two antiviral CHB therapies under investigation are JNJ-73763989 (JNJ-3989) and JNJ-56136379 (JNJ-6379; bersacapavir). JNJ-3989 is composed of 2 liver-targeted small interfering RNA (siRNA) administered subcutaneously (SC). JNJ-3989 engages endogenous RNA interference to cleave HBV RNA transcripts resulting in reduced levels of all HBV proteins and pregenomic RNA.⁴ JNJ-6379, an orally administered capsid assembly modulator (CAM), inhibits HBV replication by interfering with capsid assembly and causing the formation of empty capsids (class CAM-E)⁵ that lack HBV DNA and RNA.^{6,7} Both of these therapeutics have shown antiviral activity and good safety profiles in patients.^{4,8,9}

The phase 2b REEF-1 study (ClinicalTrials.gov Identifier: NCT03982186) investigated 48 weeks of combination treatment with JNJ-3989 and/or JNJ-6379 with NA in hepatitis B e-antigen (HBeAg)-positive or -negative patients who were either not currently treated (NCT) or NA suppressed.¹⁰ NA treatment was discontinued at end of treatment (EOT) if patients met predefined NA stopping criteria. Forty-eight weeks of treatment with JNJ-3989 dose-dependently reduced HBsAg; at EOT, nearly 75% of patients treated with the highest dose of JNJ-3989 (200 mg) reached HBsAg <100 IU/mL and 30% met NA stopping criteria.

Studies have shown that controlled NA cessation can induce HBsAg seroclearance in patients with HBeAg-negative CHB,^{11,12} but the rate varies with generally higher rates in European versus Asian patients.^{13,14} According to the international treatment guidelines for the management of CHB by the European Association for the Study of the Liver (EASL),¹⁵ controlled withdrawal of NA treatment can be considered in non-cirrhotic patients with long-term (≥ 3 years) NA-suppression and HBeAg-negative CHB if appropriate follow-up is conducted.^{16,17,18} Multiple cohort studies of NA withdrawal after long-term treatment suggest that low levels of HBsAg (preferentially < 100 IU/mL) when NA is discontinued are associated with higher likelihood of achieving HBsAg seroclearance and lower risk of viral and biochemical relapse.¹⁹ The REEF-2 study assessed whether reduction of HBsAg to low levels with 48 weeks of JNJ-3989 treatment (plus viral suppression with NA and JNJ-6379), followed by NA withdrawal, leads to functional cure in the described population.

The primary objective of this study was to evaluate the efficacy of the REEF-2 treatment regimen and NA stopping as assessed by off-treatment HBsAg seroclearance 24 weeks after completion of the 48-week treatment phase. Secondary objectives included change in virologic parameters over time and evaluation of safety and tolerability.

Patients and methods

Study design and patients

REEF-2, a phase 2b, double-blind, placebo-controlled, randomized study (ClinicalTrials.gov Identifier: NCT04129554), was conducted at 33 centers in 7 European countries (Belgium, France, Germany, Italy, Poland, Spain, and the United Kingdom). Noncirrhotic patients aged 18 to 65 with HBeAg-negative CHB who were virologically suppressed with NA treatment for ≥ 24

months prior to screening were enrolled (**Supplementary Figure 1**). Eligible patients had HBsAg >100 IU/mL at screening, and HBV DNA <60 IU/mL and alanine aminotransferase (ALT) <2.0× upper limit of normal (ULN) on 2 measurements ≥6 months apart (1 at screening).

Patients were randomized (2:1) to receive JNJ-3989 (200 mg SC injection every 4 weeks [Q4W]) + JNJ-6379 (250 mg oral [PO] tablets daily [QD]) + NA (entecavir, tenofovir alafenamide, or tenofovir disoproxil fumarate QD; active arm) or JNJ-3989 placebo (SC Q4W) + JNJ-6379 placebo (PO QD) + NA (control arm; **Supplementary Fig. 1**). Patients received treatment for 48 weeks and then discontinued all treatments, including NA, without the requirement to meet pre-specified criteria; this was followed by a 48-week off-treatment follow-up phase. NA retreatment criteria during follow-up were: confirmed HBeAg seroreversion, HBV DNA increase >2000 IU/mL and ALT >5× ULN, HBV DNA increase >20,000 IU/mL. NA treatment was restarted immediately with signs of decreasing or impaired liver function indicated by laboratory or clinical assessments or with HBV DNA >100,000 IU/mL, regardless of ALT levels (this last criterium was added during the study via protocol amendment).

This study was conducted according to ethical principles that have their origin in the Declaration of Helsinki and are consistent with Good Clinical Practice. Study protocols were approved by the local independent ethics committee/institutional review board. Written informed consent was obtained from all study patients.

Endpoints and assessments

The primary endpoint was the proportion of patients who achieved functional cure, defined as HBsAg seroclearance (<lower limit of quantification [LLOQ] = 0.05 IU/mL) at Follow-up Week 24, without restarting NA treatment. Secondary efficacy endpoints included the proportion of

patients who achieved HBsAg seroclearance at Week 48 and Follow-up Week 48 without restarting NA, proportion of patients with HBV DNA <LLOQ (20 IU/mL) at Week 48 and <LLOQ or <2000 IU/mL at Follow-up Week 48, change from baseline over time in HBsAg, HBV DNA, and ALT, proportion of patients achieving certain thresholds of HBsAg (eg, HBsAg <100, <10, and <1, and <0.05 [seroclearance] IU/mL), and proportion of patients with clinical relapse (ie, HBV DNA >2000 IU/mL increases with ALT flares [confirmed ALT $\geq 3 \times$ ULN and $\geq 3 \times$ nadir]).

Safety and tolerability of the study drugs were evaluated by assessments for adverse events (AEs), abnormal clinical laboratory tests, 12-lead electrocardiogram, vital signs, and physical examination. Patient safety was assured through inclusion of an independent data monitoring committee and an independent flare expert panel that reviewed and adjudicated all ALT flares.

Statistical analysis

The total planned sample size was 120 patients, with 80 and 40 allocated to the active and control arms, respectively. All efficacy data were analyzed by treatment arm (active vs control), analysis phase (double-blind treatment phase vs off-treatment follow-up), and over time (when applicable). The modified intent-to-treat (mITT) analysis set was the primary population used for efficacy analyses and included all patients who were randomized and received ≥ 1 dose of study drug, excluding those impacted by the COVID-19 pandemic (eg, those who, because of COVID-19 or similar pandemic-related reasons, withdrew from the study prior to Week 72, or had no efficacy assessment for the primary endpoint). The safety population included all patients who received ≥ 1 dose of any study drug.

Results

Patients

NA suppressed, HBeAg-negative CHB patients (N = 130) were enrolled at European sites with study initiation on November 7, 2019 and study completion on June 9, 2022. Eighty-five and 45 patients were randomized to the active and control arms, respectively (**Figure 1; Supplementary Fig. 1**). The mITT population included 128 patients, excluding 2 who withdrew for COVID-19-related reasons (**Figure 1**). Overall, 66.9% of patients were male, 66.2% were White, 19.2% were Asian, the mean age was 46.0 years; the mean duration of NA treatment at study entry was 8.3 years (**Table 1**). All patients had baseline HBV DNA <LLOQ, and the mean (standard deviation [SD]) baseline HBsAg for the active and control arms were 3.43 (0.53) and 3.49 (0.70) IU/mL, respectively.

Of the 130 patients enrolled, 81 (95.3%) and 40 (88.9%) in the active and control arms, respectively, completed the study (**Figure 1**). Most premature study terminations were due to patient choice and only 8 (9.4%) and 4 (8.9%) patients in the active and control arms, respectively, discontinued treatment with JNJ-3989, JNJ-6379, or placebo prematurely (**Figure 1**).

Efficacy

Primary endpoint

At Follow-up Week 24, no patients achieved the primary endpoint of functional cure (off-treatment HBsAg seroclearance), and no patients achieved functional cure at Follow-up Week 48 (end of the follow-up; **Figure 2**).

HBsAg values

The secondary endpoint, mean (standard error [SE]; range) HBsAg change from baseline at Week 48, was -1.89 (0.06; $-3.4, -1.0$) \log_{10} IU/mL in the active arm and -0.06 (0.01; $-0.3, 0.2$) \log_{10} IU/mL in the control arm ($P < 0.001$; **Figure 3A; Table 2; Supplementary Fig. 2**).

Preliminary multivariate analyses of the association between baseline factors (race, age, sex, NA-treatment duration, and baseline HBsAg level) and $>2 \log_{10}$ IU/mL reduction in HBsAg from baseline at Week 48 did not identify a significant factor ($P < 0.05$), though Asian race (odds ratio [OR; 95% confidence interval (CI)] = 2.2 [0.7, 7.5]; $P = 0.189$) and higher baseline HBsAg levels (OR [95% CI] = 2.1 [0.7, 5.9]; $P = 0.159$) demonstrated a trend for an association (**Supplementary Table 1**). By Follow-up Week 48, mean (SE; range) HBsAg change from baseline was -1.46 (0.07; $-4.0, -0.3$) \log_{10} IU/mL in the active arm and -0.49 (0.12; $-4.5, 0.1$) \log_{10} IU/mL in the control arm ($P < 0.001$; **Figure 3A; Table 2; Supplementary Fig. 2**). At Week 48, Follow-up Week 24, and Follow-up Week 48, 54/76 (71.1%), 53/79 (67.1%), and 38/81 (46.9%) patients in the active arm, respectively, achieved HBsAg <100 IU/mL versus 1/41 (2.4%), 4/39 (10.3%), and 6/40 (15.0%) patients in the control arm at these time points (**Figure 2**).

Though mean HBsAg levels increased in the active arm after EOT, reductions from baseline were $>1 \log_{10}$ IU/mL in 81.5% of patients at Follow-up Week 48 versus 12.5% in the control arm (**Supplementary Fig. 2**). Furthermore, 13.2% and 18.4% of patients in the active arm had declining ($>0.2 \log_{10}$ IU/mL reduction) or stable ($\pm 0.2 \log_{10}$ IU/mL change) HBsAg levels, respectively, from Week 48 to Follow-up Week 48 (**Supplementary Fig. 3**).

One patient in the active arm achieved transient HBsAg seroclearance from Follow-up Week 28 to Follow-up Week 36, and 1 in the control arm achieved HBsAg seroclearance at Follow-up

Week 36 until the end of the study after a clinical flare (ALT and/or aspartate transferase [AST] $>3\times$ ULN and $>3\times$ nadir) and restarting NA. Two additional patients, 1 in each arm, became HBsAg seronegative as a result of liver transplantation that was required due to hepatocellular carcinoma on continued NA for the active arm patient and severe HBV reactivation for the control arm patient.²⁰

On-treatment response

All patients had baseline HBV DNA levels $<$ LLOQ (20 IU/mL), which was maintained in 73/75 (97.3%) and 41/41 (100%) in the active and control arms, respectively, at Week 48 (**Figure 4**). There was no viral breakthrough (ie, confirmed [2 consecutive visits] 1 log₁₀ IU/mL increase from nadir or confirmed HBV DNA >200 IU/mL if nadir was HBV DNA $<$ LLOQ) during the 48-week treatment phase for either arm. Mean ALT values remained near baseline levels during the treatment phase; there was a gradual increase in the active arm with 16 of 76 (21.1%) patients having ALT $>2\times$ their baseline value (versus none in the control arm). Mean ALT levels remained in the normal range (**Figure 5**).

Off-treatment response

Off-treatment clinical relapse (ie, HBV DNA >2000 IU/mL increases with ALT flares [confirmed ALT $\geq 3\times$ ULN and $\geq 3\times$ nadir]) were observed in 3/77 (3.9%) and 11/41 (26.8%) patients in the active and control arms, respectively. Increases in HBV DNA during follow-up correlated with ALT increases (active: $P = 0.0059$; control: $P < 0.0001$; **Supplementary Fig. 4**), and peak HBV DNA levels $>100,000$ IU/mL were associated with ALT flares $\geq 3\times$ ULN. In patients with virologic relapse with confirmed off-treatment peak HBV DNA $>100,000$ IU/mL, peak ALT $>3\times$ ULN was observed in 1/2 (50%) and 11/11 (100%) patients in the (active and

control arms, respectively). HBV DNA increases were less frequent and less pronounced in the active arm (peak HBV DNA >2000 IU/mL: active = 33.8%, control = 65.8%; peak HBV DNA >100,000 IU/mL [virologic relapse]: active = 2.6%, control = 26.8%, OR [95% CI] = 9.1 [2.4, 34.3], $P = 0.001$; **Supplementary Table 2**), resulting in a substantially lower rate of ALT flares (active = 3.6%, control = 28.6%) during follow-up. Seven cases of off-treatment transient HBeAg-positivity were observed, and most were in patients from the control arm who met NA retreatment criteria (**Supplementary Table 3**). Few patients in the active arm had ALT flares during the follow-up phase with 73/77 (94.8%) having peak ALT levels <3× ULN versus 25/41 (61.0%) in the control arm (**Table 2**). In contrast, 10/41 (24.3%) of these patients in the control arm had peak ALT levels ≥10× ULN versus only 1/77 (1.3%) in the active arm (OR [95% CI] = 28.3 [3.3, 245.6], $P = 0.002$; **Table 2; Supplementary Table 2**). Within the active arm, no significant association was observed between baseline characteristics, including race, sex, age, and NA treatment duration and HBV DNA >100,000 IU/ml (virologic relapse) or ALT ≥10× ULN (**Supplementary Table 4**).

Seven of 77 (9.1%) patients in the active arm and 11/41 (26.8%) patients in the control arm met NA retreatment criteria at any time during follow-up (OR [95% CI] = 0.2 [0.1, 0.6], $P = 0.006$; **Figure 3B; Supplementary Tables 2 and 3**). Of patients who met retreatment criteria, confirmed increases in HBV DNA >20,000 IU/mL was the most common reason patients met retreatment criteria during follow-up (active: 3/3 [100%]; control: 9/10 [90.0%]). Other reasons in the control arm included HBV DNA increase >2000 IU/mL and ALT >5× ULN (6/10 [60.0%]), HBeAg seroreversion (3/10 [30.0%]), and signs of reduced liver function (1/10 [10.0%]). During the follow-up, 1 patient in the control arm developed a serious AE (SAE) related to discontinuation of NA. Though this patient restarted NA treatment immediately when

indicated by the restarting criteria, severe HBV reactivation and acute liver failure necessitating urgent liver transplant, which was successful, was required.²⁰

Among patients who stopped NA, at Follow-up Week 48, 17/77 (22.1%) and 1/41 (2.4%) patients in the active and control arms, respectively, had HBV DNA <LLOQ; 31/77 (40.3%) and 3/41 (7.3%) in the active and control arms, respectively, had HBV DNA <2000 IU/mL and HBsAg <100 IU/mL; and 12/77 (15.6%) and 0 in the active and control arms, respectively, had HBV DNA <LLOQ and HBsAg <100 IU/mL, which is commonly referred to as partial cure²¹ (**Table 2**).

Safety

Safety was evaluated as a secondary endpoint throughout the study. During the 48-week treatment phase, ≥ 1 AE was experienced by 69 (81.2%) patients in the active arm, 38 (44.7%) of whom had AEs related to treatment, and by 32 (71.1%) patients in the control arm, 15 (33.3%) of whom had AEs related to treatment (**Table 3**). During the 48-week follow-up phase, 55 (65.5%) and 28 (68.3%) patients in the active and control arms, respectively, experienced ≥ 1 AE. During treatment, grade 3 or 4 AEs were experienced by 13 (15.3%) and 2 (4.4%) patients in the active and control arms, respectively, most of which were grade 3 (active: 11 [12.9%]; control: 1 [2.2%]). Six (4.6%) patients had grade 3 or 4 AEs related to study treatment, all of whom belonged to the active arm. The majority of grade 3 AEs and 4 of the 6 related grade 3 AEs during the doubleblind phase were reported as reduction in eGFR based on creatinine levels. During follow-up, grade 3 or 4 AEs were experienced by 7 patients from each arm, and only 1 patient from each arm had a grade 3 or 4 AE related to the study drug. Rates of SAEs were low for both arms during the treatment phase, occurring in 2 (2.4%) and 1 (2.2%) patient in the active

and control arms, respectively, and during the follow-up, occurring in 2 (2.4%) and 3 (7.3%) patients in the active and control arms. There were no deaths.

Discussion

Potential treatment regimens for CHB that aim to provide functional cure, by definition, should be finite. Different studies suggest that NA discontinuation may be a mechanism to achieve HBsAg loss in a subset of noncirrhotic, HBeAg-negative patients who are virologically suppressed from NA treatment.^{15,17,18} While factors associated with off-treatment response (and absence of relapse) are not completely established, low HBsAg levels, preferentially <100 IU/mL, at the time of NA discontinuation have been shown to be the best predictor of success (ie, HBsAg loss).^{15,11} The REEF-2 study explored the effect of NA stopping in VS HBeAg-negative patients treated with NA, with or without JNJ-3989 and JNJ-6379, to assess whether increasing the proportion of patients with HBsAg levels <100 IU/mL prior to stopping NA treatment increases the efficacy of treatment discontinuation.

The primary endpoint of the study, functional cure at Follow-up Week 24, was not achieved by any patients. Based on previous NA stop studies that included European cohorts on long-term NA treatment,^{13,19,22,11} the rate of HBsAg decline and loss observed in the control arm was lower than expected; only 1 patient in this arm achieved HBsAg loss at Follow-up Week 36 after a viral relapse with ALT flare that required NA retreatment. The limited HBsAg decline observed is likely explained by the fact that only 31.7% of patients had HBsAg <1000 IU/mL and only 1 patient in the control arm had HBsAg <100 IU/mL at the time of NA stopping.^{13,19,22,23} Of note, this patient had EOT HBsAg of 65 IU/mL and a 1.12 log₁₀ reduction in HBsAg from EOT with relatively stable levels from Follow-up Week 24 to 48.

Although functional cure was not achieved, pronounced and sustained JNJ-3989-induced declines in HBsAg levels were observed for patients in the active arm, with 71.1% of these patients achieving HBsAg <100 IU/mL at EOT, which was maintained in 46.9% of patients at Follow-up Week 48. Even with this high proportion of patients in the active arm achieving HBsAg <100 IU/mL at Week 48, only 1 achieved transient HBsAg seroclearance during the 48-week follow-up phase. This indicates that induced reduction of HBsAg levels with an HBsAg-targeting siRNA is different from naturally achieved low HBsAg, with or without NA treatment, in terms of increasing the probability of achieving HBsAg seroclearance. While during follow-up most patients in the active arm had slowly increasing HBsAg levels, 32% showed no increase and 13% had further reductions of HBsAg after the EOT. Mean HBsAg reductions from baseline were 1.89 log₁₀ at EOT and 1.46 log₁₀ at the end of follow-up in the active arm, and 0.06 log₁₀ and 0.49 log₁₀, respectively, in the control arm. The observed reduction of HBsAg in some control arm patients and only slow increase in the active arm, with 32% of active arm patients having no increase, may be related to the immune-stimulating effect of stopping NA.

A potential limitation of our study is the relatively short 48-week follow-up period, as HBsAg seroclearance, virologic relapse, biochemical flares, and/or other clinical outcomes can occur over multiple years after NA cessation.^{11,19,24} Additional analyses are needed to characterize the immune changes associated with the reduction of HBsAg under JNJ-3989 treatment versus natural or NA treatment-associated low HBsAg levels. Another potential limitation is the length of the treatment phase (ie, 48 weeks); a longer duration of HBsAg suppression from an extended treatment period may be required to achieve functional cure. Lastly, similar to other large clinical studies in CHB, no liver biopsies were taken, and thus assessment of viral or immune changes in the liver could not be performed.

In the REEF-1 study, patients treated with JNJ-3989 and NA without JNJ-6379 had greater reductions in mean HBsAg levels than patients treated with JNJ-3989 and NA in combination with JNJ-6379.¹⁰ The underlying mechanism of this observation is not understood, but the current study provides support for the REEF-1 findings that there is no added benefit to on-treatment HBsAg decline from adding JNJ-6379 to JNJ-3989.

A higher proportion of patients in the active versus control arm reached off-treatment cutoffs for HBsAg and HBV DNA (eg, 43.7% <2000 IU/mL + HBsAg <100 IU/mL and 16.9% HBV DNA <LLOQ + HBsAg <100 IU/mL). While functional cure is the ideal treatment goal, durable suppression of viral parameters in the absence of antiviral therapy may be an acceptable treatment goal leading to improved clinical outcomes and survival rates.^{3,21}

During the follow-up phase, a greater proportion of patients in the control arm experienced off-treatment virologic and clinical relapses, with peak HBV DNA >100,000 IU/mL and peak ALT $\geq 10 \times$ ULN versus the active arm. Consequently, more patients in the control (27.3%) versus active (7.1%) arm required NA retreatment. Treatment with JNJ-3989 decreased the risk of severe off-treatment HBV DNA increases and ALT flares and increased the chance of sustained, “indolent,” off treatment HBV DNA and HBsAg suppression. Longer follow-up data are needed to confirm the sustained off-treatment response in the active arm and to assess potential late relapses and/or events of HBsAg seroclearance.

The treatment regimens in REEF-2 were safe and well-tolerated, consistent with other studies.^{4,10} The rates of (S)AEs, laboratory abnormalities, and early treatment discontinuation were similar to those observed in the REEF-1 study arm that included JNJ-3989, JNJ-6379, and NA.¹⁰ Similar proportions of patients from each arm of this study experienced SAEs during each phase, however, a higher rate of patients in the active arm experienced AEs and grade 3 or 4 AEs (most

cases reported were grade 3 reductions of eGFR) compared with the control arm. Importantly, the higher rate of overall AEs in the active arm did not result in an increased rate of AEs leading to discontinuation of the study treatment or death. One patient in the control arm who stopped NA treatment experienced HBV DNA elevations with delayed ALT, meeting the criteria for NA retreatment at Follow-up Week 11.²⁰ Despite initiation of NA treatment, this patient experienced sub-acute liver failure and successfully underwent liver transplantation.²⁰ Based on this case, the protocol-specified criteria for NA retreatment were modified to initiate NA retreatment immediately in case of HBV DNA >100,000 IU/mL, irrespective of ALT levels. With these adapted criteria, stopping NA was generally safe. This unfavorable outcome of NA termination underscores the potential risk of this stopping NA intervention as well as the importance of close monitoring and early retreatment.

The REEF-2 trial represents, to date, the largest prospective, randomized study on treatment discontinuation in CHB patients with consistent management of NA retreatment according to protocol-specified criteria. The findings provide important insights for future study design with finite treatment approaches. REEF-2 recruited fully, despite the COVID-19 pandemic, and the attrition rate was very low, a testament to the patients and expert clinical sites. The lack of functional cure in this trial could potentially be attributed to the exclusion of patients with HBsAg levels <100 IU/mL at screening. Of note, although REEF-2 recruited only at European sites, 19% of the enrolled patients were Asian.

In conclusion, in the REEF-2 study, the combination of JNJ-3989 + JNJ-6379 + NA resulted in fewer and less severe posttreatment HBV DNA increases and ALT flares, versus NA-only treatment, and led to sustained off-treatment HBV DNA and HBsAg suppression, but functional

cure from CHB was not achieved. Combination regimens of JNJ-3989 with immunomodulators are being explored and may be necessary to achieve functional cure.

Abbreviations

AE, adverse event; ALT, alanine aminotransferase; AST, aspartate transferase; CAM-E, capsid assembly modulator-empty; CHB, chronic hepatitis B; EASL, European Association for the Study of the Liver; eGFR, estimated glomerular filtration rate; EOT, end of treatment; ETV, entecavir; F, follow-up; HBcrAg, hepatitis B core-related antigen; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; JNJ-3989, JNJ-73763989; JNJ-6379, JNJ-56136379; LLOQ, lower limit of quantification; mITT, modified intent-to-treat; NA, nucleos(t)ide analog; NCT, not currently treated; PO, oral; Q4W, every 4 weeks; QD, daily; SAEs, serious adverse events; siRNA, small interfering RNA; SC, subcutaneous; SD, standard deviation; SE, standard error; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; ULN, upper limit of normal.

Acknowledgments

The authors thank the patients in these studies and the other Janssen staff members for their contributions to the studies. This study was sponsored by Janssen Research & Development, LLC, with medical writing support provided by Kim Caldwell, PhD, of Lumanity Communications Inc., and funded by Janssen Research & Development, LLC.

Data availability

The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at <https://www.janssen.com/clinical-trials/transparency>. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at <http://yoda.yale.edu>.

References

- [1] Yuen MF, Chen DS, Dusheiko GM, et al. Hepatitis B virus infection. *Nat Rev Dis Primers* 2018;4:18035.
- [2] Lok AS, McMahon BJ, Brown RS, Jr., et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. *Hepatology* 2016;63:284-306.
- [3] Lok AS, Zoulim F, Dusheiko G, et al. Hepatitis B cure: from discovery to regulatory approval. *Hepatology* 2017;66:1296-1313.
- [4] Yuen MF, Locarnini S, Lim TH, et al. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB. *J Hepatol* 2022;77:1287-1298.
- [5] **Zoulim F, Zlotnick A**, Buchholz S, et al. Nomenclature of HBV core protein-targeting antivirals. *Nat Rev Gastroenterol Hepatol* 2022;19:748-750.
- [6] Janssen HLA, Hou J, Asselah T, et al. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection. *Gut* 2023.

- [7] Verbinnen T, Hodari M, Talloen W, et al. Virology analysis of chronic hepatitis B virus-infected patients treated for 28 days with JNJ-56136379 monotherapy. *J Viral Hepat* 2020;27:1127-1137.
- [8] Verbinnen T, Tan Y, Wang G, et al. Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A-H clinical isolates and core site-directed mutants in vitro. *J Antimicrob Chemother* 2020;75:2526-2534.
- [9] Zoulim F, Lenz O, Vandenbossche JJ, et al. JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection. *Gastroenterology* 2020;159:521-533 e529.
- [10] Yuen MF, Asselah T, Jacobson IM, et al. Efficacy and safety of the siRNA JNJ-73763989 and/or the capsid assembly modulator JNJ-56136379 (bersacapavir) for the treatment of chronic hepatitis b virus infection: results from the phase 2b REEF-1 study. *Lancet Gastroenterol & Hepatol* 2023;8(9):790-802.
- [11] van Bömmel F, Stein K, Heyne R, et al. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B. *J Hepatol* 2023.
- [12] Hall SAL, Burns GS, Anagnostou D, et al. Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels. *Aliment Pharmacol Ther* 2022;56:310-320.
- [13] Berg T, Simon KG, Mauss S, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. *J Hepatol* 2017;67:918-924.

- [14] van Bommel F, Berg T. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B. *Hepatol Commun* 2021;5:1632-1648.
- [15] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol* 2017;67:370-398.
- [16] Cornberg M, Wong VW, Locarnini S, et al. The role of quantitative hepatitis B surface antigen revisited. *J Hepatol* 2017;66:398-411.
- [17] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology* 2018;67:1560-1599.
- [18] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatol Int* 2016;10:1-98.
- [19] Hirode G, Choi HSJ, Chen CH, et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B Study). *Gastroenterology* 2022;162:757-771 e754.
- [20] Agarwal K, Lok J, Carey I, et al. A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'. *J Hepatol* 2022;77:245-248.
- [21] Ghany MG, Buti M, Lampertico P, et al. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV/HDV treatment endpoints conference. *J Hepatol* 2023;79(5):1254-1269.

- [22] Lampertico P, Berg T. Less can be more: A finite treatment approach for HBeAg-negative chronic hepatitis B. *Hepatology* 2018;68:397-400.
- [23] van Bömmel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. *Hepatology* 2015;61:66-76.
- [24] Dongelmans E, Hirode G, Hansen B, et al. Predictors of severe flares after nucleos (t)ide analogue cessation-results of a global cohort study (RETRACT-B study). Oral Presentation presented at EASL - European Association for the Study of the Liver, June 21-24, 2023.

Table 1. Demographics and Baseline Characteristics for the ITT Population*

	JNJ-3989 +		
	Placebos + NA	JNJ-6379 + NA	Total
	(control)	(active)	
	n = 45	n = 85	N = 130
Sex, n (%)			
Male	29 (64.4)	58 (68.2)	87 (66.9)
Female	16 (35.6)	27 (31.8)	43 (33.1)
Age, years	47.4 (10.55)	45.3 (10.10)	46.0 (10.27)
Race, n (%)			
White	30 (66.7)	56 (65.9)	86 (66.2)
Asian	8 (17.8)	17 (20.0)	25 (19.2)
Black or African American	5 (11.1)	7 (8.2)	12 (9.2)
Not reported	1 (2.2)	4 (4.7)	5 (3.8)
Unknown	1 (2.2)	1 (1.2)	2 (1.5)
Disease characteristics			
HBsAg, log ₁₀ IU/mL	3.49 (0.703)	3.43 (0.530)	3.45 (0.594)
HBsAg level: <100 IU/mL, n (%)	1 (2.2)	0	1 (0.8)
HBV DNA <LLOQ, n (%) [†]	45 (100)	85 (100)	130 (100)
HBV RNA <LOD, n (%) [‡]	42 (97.7) [§]	77 (92.8) [§]	119 (94.4) [§]
HBcrAg <LLOQ, n (%)	33 (75.0) [§]	56 (65.9)	89 (69.0) [§]
ALT, U/L	23.9 (10.75)	24.2 (10.89)	24.1 (10.80)

Fibroscan score, kPa	5.02 (1.301)	5.23 (1.482)	5.16 (1.420)
Duration of NA at study entry, years	8.1 (4.48)	8.4 (4.79)	8.3 (4.67)
<hr/>			
Stratification factors, %			
Asian vs non-Asian	17.8/82.2	20.0/80.0	19.2/80.8
Type of NA: ETV vs TDF/TAF [¶]	37.8/62.2	38.8/61.2	38.5/61.5
HBsAg level: <1000 vs ≥1000 IU/mL	24.4/75.6	20.0/80.0	21.5/78.5

ALT, alanine aminotransferase; ETV, entecavir; HBcrAg, hepatitis B core-related antigen;

HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; ITT, intent-to-treat; JNJ-3989, JNJ-73763989; JNJ-6379; JNJ-56136379; LLOQ, lower limit of quantification; LOD, limit of detection; NA, nucleos(t)ide analog; SD, standard deviation; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

*Values are mean (SD) unless otherwise noted.

†HBV DNA, LLOQ = 20 IU/mL.

‡HBV RNA, LOD = 2.49 log₁₀ copies/mL.

§Number of patients in the denominator differs from ITT population.

||HBcrAg, LLOQ = 3.0 log₁₀ U/mL.

¶Two patients were on TAF.

Table 2. HBsAg, ALT, and HBV DNA Values*

	Placebos + NA (control) n = 45			JNJ-3989 + JNJ-6379 + NA (active) n = 85		
HBsAg, mean (SE), log ₁₀ IU/mL	Baseline	Change from baseline at Week 48	Change from baseline at Follow-up Week 48	Baseline	Change from baseline at Week 48	Change from baseline at Follow-up Week 48
	3.49 (0.11)	-0.06 (0.01)	-0.49 (0.12)	3.43 (0.06)	-1.89 (0.06) [†]	-1.46 (0.07) [†]
HBsAg	Baseline	Week 48	Follow-up Week 48	Baseline	Week 48	Follow-up Week 48
<100 IU/mL	1/44 (2.3)	1/41 (2.4)	6/40 (15.0)	0	54/76 (71.1)	38/81 (46.9)
<10 IU/mL	0	0	3/40 (7.5)	0	15/76 (19.7)	12/81 (14.8)
<LLOQ [‡]	-	0	1/40 (2.5)	-	0	0
≥1 log ₁₀ reduction from baseline	-	0	5/40 (12.5)	-	76/76 (100)	66/81 (81.5)
≥2 log ₁₀ reduction from baseline	-	0	1/40 (2.5)	-	25/76 (32.9)	13/81 (16.0)
	HBV DNA <2000 IU/mL	HBV DNA < LLOQ [#]		HBV DNA <2000 IU/mL	HBV DNA <LLOQ [#]	

Off-treatment HBV DNA at Follow-up Week 48 [§]	19/41 (46.3)	1/41 (2.4)	62/77 (80.5) [¶]	17/77 (22.1) [¶]				
	HBV DNA <2000 IU/mL and HBsAg <100 IU/mL	HBV DNA <LLOQ[#] and HBsAg <100 IU/mL	HBV DNA <2000 IU/mL and HBsAg <100 IU/mL	HBV DNA <LLOQ[#] and HBsAg <100 IU/mL				
Off-treatment HBV DNA and HBsAg at Follow-up Week 48 [§]	3/41 (7.3)	0	31/77 (40.3) [¶]	12/77 (15.6) [¶]				
	>2000 IU/mL	>100,000 IU/mL	>2000 IU/mL	>100,000 IU/mL				
Off-treatment virologic relapse** by peak HBV DNA	27/41 (65.8)	11/41 (26.8)	26/77 (33.8)	2/77 (2.6)				
ALT flare ^{††} during follow-up	12/42 (28.6)		3/83 (3.6)					
	<3× ULN	≥3× to <5× ULN	≥5× to <10× ULN	≥10× ULN	<3× ULN	≥3× to <5× ULN	≥5× to <10× ULN	≥10× ULN
ALT peak level during follow-up	25/41 (61.0)	2/41 (4.9)	4/41 (9.8)	10/41 (24.3)	73/77 (94.8)	2/77 (2.6)	1/77 (1.3)	1/77 (1.3)
	>2000 IU/mL	>100,000 IU/mL	>2000 IU/mL	>100,000 IU/mL	>2000 IU/mL	>100,000 IU/mL	>2000 IU/mL	>100,000 IU/mL
Off-treatment clinical relapse ^{‡‡} by peak HBV DNA	11/41 (26.8)	11/41 (26.8)	3/77 (3.9)	1/77 (1.3)				

NA retreatment	12/44 (27.3)	6/84 (7.1)
----------------	--------------	------------

ALT, alanine aminotransferase; AST, aspartate transaminase; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; JNJ-3989, JNJ-73763989; JNJ-6379, JNJ-56136379; LLOQ, lower limit of quantification; NA, nucleos(t)ide analog; SE, standard error.

*Values are n/N (%) unless otherwise stated.

[†] $P < 0.001$ between arms at each time point. Mixed model repeated measures including treatment arm, analysis time point (week), their interaction, 2 randomization stratification factors (race and type of NA), baseline blood marker categorical variable, and treatment arm by baseline interaction as fixed effects.

[‡]LLOQ = $-1.3 \log_{10} \text{ IU/mL} = 0.05 \text{ IU/mL}$.

[§]Patients with off-treatment HBV DNA suppression at Follow-up Week 48. All patients who stopped NA are included in the denominator, while the numerators include patients who remained off-treatment at Follow-up Week 48 and met the thresholds for each treatment arm.

^{||}Of 41 patients with off-treatment data during follow-up, 12 (27.3%) restarted NA, 1 (2.4%) dropped out before Follow-up Week 48 without restarting NA, and 28 (68.3%) were off-treatment at Follow-up Week 48.

[¶]Of 77 patients with off-treatment data during follow-up, 6 (7.8%) restarted NA, 0 dropped out before Follow-up Week 48 without restarting NA, and 71 (92.2%) were off-treatment at Follow-up Week 48.

[#]LLOQ = $1.3 \log_{10} \text{ IU/mL} = 20 \text{ IU/mL}$.

**Confirmed HBV DNA >peak threshold.

††Confirmed ALT $\geq 3 \times$ ULN and $\geq 3 \times$ nadir.

‡‡Confirmed HBV DNA >peak threshold and confirmed ALT and/or AST $\geq 3 \times$ ULN and $\geq 3 \times$ nadir.

Journal Pre-proof

Table 3. AEs During the 48-week Double-blind Treatment Phase and 48-week Off-treatment Follow-up Phase

	48-week double-blind treatment phase		48-week off-treatment follow-up phase	
	JNJ-3989 +		JNJ-3989 +	
	Placebos + NA	JNJ-6379 + NA	Placebos + NA	JNJ-6379 + NA
	(control) n = 45	(active) n = 85	(control) n = 41	(active) n = 84
AEs	32 (71.1)	69 (81.2)	28 (68.3)	55 (65.5)
Related AEs	15 (33.3)	38 (44.7)	1 (2.4)	1 (1.2)
JNJ-3989/placebo	12 (26.7)	34 (40.0)	1 (2.4)	1 (1.2)
JNJ-6379/placebo	11 (24.4)	36 (42.4)	1 (2.4)	1 (1.2)
NA (ETV/TDF/TAF)	3 (6.7)	10 (11.8)	0	1 (1.2)
AEs leading to death	0	0	0	0
SAEs	1 (2.2)	2 (2.4)	3 (7.3)	2 (2.4)
Related SAEs	0	0	1 (2.4)*	0
AEs leading to discontinuation of JNJ-6379 and/or JNJ-3989	1 (2.2)	3 (3.5)	-	-
Grade 3 or 4 AEs	2 (4.4)	13 (15.3)	7 (17.1)	7 (8.3)
ALT increased	0	0	4 (9.8)	2 (2.4)
eGFR decreased [†]	0	6 (7.1)	0	1 (1.2)
AEs of special interest	8 (17.8)	29 (34.1)	11 (26.8)	7 (8.3)
Renal complications	5 (11.1)	21 (24.7)	0	2 (2.4)

Injection-site reactions	0	4 (4.7)	0	0
Hematologic abnormalities	2 (4.4)	2 (2.4)	1 (2.4)	2 (2.4)
ALT/AST elevations	1 (2.2)	3 (3.5)	10 (24.4)	5 (6.0)
Cholesterol increases	2 (4.4)	1 (1.2)	0	1 (1.2)
Most common AEs ($\geq 10\%$ of patients during the double-blind or follow-up phases)				
eGFR decrease (≥ 10 to $< 30\%$ decline)	4 (8.9)	17 (20.0)	–	–
Headache	5 (11.1)	15 (17.6)	6 (14.6)	8 (9.5)
Arthralgia	6 (13.3)	7 (8.2)	6 (14.6)	2 (2.4)
Back pain	5 (11.1)	7 (8.2)	1 (2.4)	5 (6.0)
COVID-19	2 (4.4)	9 (10.6)	2 (4.9)	10 (11.9)
ALT increase	1 (2.2)	3 (3.5)	10 (24.4)	5 (6.0)

AEs, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; ETV, entecavir; JNJ-3989, JNJ-73763989; JNJ-6379, JNJ-56136379; NA, nucleos(t)ide analog; SAEs, serious adverse events; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

*One patient experienced severe acute liver failure after stopping NA that was considered related to study procedure.²⁰

†Likely due to JNJ-6379 based on its known profile; this was reversible at the end of therapy.

Most events designated by investigators as related to treatment, except for in one patient in each phase.

Journal Pre-proof

Figure legends**Fig. 1. Study flow diagram.**

AE, adverse event; JNJ-3989, JNJ-73763989; JNJ-6379, JNJ-56136379; mITT, modified intent-to-treat; NA, nucleos(t)ide analog.

*One patient's decision was COVID-19 related. The patients (1 in each arm) who withdrew prematurely due to COVID-19-related reasons were excluded from the mITT analysis.

Fig. 2. Proportion of patients who met HBsAg thresholds by time point/visit.

HBsAg, hepatitis B surface antigen; JNJ-3989, JNJ-73763989; JNJ-6379, JNJ-56136379; NA, nucleos(t)ide analog.

Fig. 3. Mean (A) and individual change (B) in HBsAg over time.

F, follow-up; HBsAg, hepatitis B surface antigen; JNJ-3989, JNJ-73763989; JNJ-6379, JNJ-56136379; LLOQ, lower limit of quantification; NA, nucleos(t)ide analog; SE, standard error.

* $P < 0.001$ between arms at each time point. Mixed model repeated measures including treatment arm, analysis time point (week), their interaction, 2 randomization stratification factors (race and type of NA), baseline blood marker categorical variable, and treatment arm by baseline interaction as fixed effects.

Fig. 4. HBV DNA over time in individual patients.

In each figure panel, the orange line is the mean for all patients.

F, follow-up; HBV, hepatitis B virus; JNJ-3989, JNJ-73763989; JNJ-6379, JNJ-56136379; NA, nucleos(t)ide analog.


Fig. 5. ALT over time in individual patients.


In each figure panel, the orange line is the mean for all patients.



ALT, alanine aminotransferase; F, follow-up; JNJ-3989, JNJ-73763989; JNJ-6379, JNJ-56136379; NA, nucleos(t)ide analog.

*Restricted to patients who stopped NA at Week 48.


Journal Pre-proof








Journal Pre-proof





Highlights

- No functional cure achieved 24 or 48 weeks after 48 weeks of JNJ-3989+JNJ-6379+NA
- All patients had pronounced declines in HBsAg after 48 weeks of JNJ-3989+JNJ-6379+NA
- Maintained HBsAg declines from JNJ-3989+JNJ-6379+NA up to 48-weeks off-treatment
- Pronounced HBV DNA and HBsAg suppression off-treatment after JNJ-3989+JNJ-6379+NA
- JNJ-3989+JNJ-6379 treatment was safe and well tolerated